Holen Sie sich die Stockscreener-App
12.22
5.20%
-0.67
Handel nachbörslich:
12.46
0.24
+1.96%
Schlusskurs vom Vortag:
$12.89
Offen:
$12.89
24-Stunden-Volumen:
44,931
Relative Volume:
0.40
Marktkapitalisierung:
$324.82M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-9.75%
1M Leistung:
-5.78%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$12.00
$12.93
1-Wochen-Bereich:
$12.00
$13.54
52-Wochen-Spanne:
$11.81
$16.20
Carlsmed Inc Stock (CARL) Company Profile
Firmenname
Carlsmed Inc
Sektor
Branche
Telefon
858-295-9290
Adresse
1800 ASTON AVENUE, CARLSBAD
Vergleichen Sie CARL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CARL
Carlsmed Inc
|
12.22 | 342.63M | 0 | 0 | 0 | 0.00 |
|
VEEV
Veeva Systems Inc
|
292.72 | 47.73B | 2.97B | 809.93M | 1.33B | 4.8743 |
|
TEM
Tempus Ai Inc
|
88.71 | 15.61B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
66.95 | 12.36B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
94.81 | 8.15B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
37.03 | 6.86B | 906.14M | -52.62M | 89.62M | -0.3621 |
Carlsmed Inc Stock (CARL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-18 | Eingeleitet | BTIG Research | Buy |
| 2025-08-18 | Eingeleitet | BofA Securities | Buy |
| 2025-08-18 | Eingeleitet | Goldman | Buy |
| 2025-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2025-08-18 | Eingeleitet | Truist | Buy |
Carlsmed Inc Aktie (CARL) Neueste Nachrichten
Carlsmed Secures $60 Million Credit Facility Amendment - MSN
Carlsmed, Inc. (CARL) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Carlsmed, Inc. (NASDAQ:CARL) Sees Significant Decrease in Short Interest - MarketBeat
Carlsmed, Inc. (CARL) Stock Price, News, Quote & History - Yahoo! Finance Canada
carlsmed, inc. Earnings dates - RTTNews
Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025 - The Manila Times
Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025 | User | thepilotnews.com - FinancialContent
Carlsmed, Inc.Common Stock (Nasdaq:CARL) Stock Quote - FinancialContent
Carlsmed, Inc. (NASDAQ:CARL) Short Interest Update - MarketBeat
ETFs Investing in Carlsmed, Inc. Stocks - TradingView
AI medtech firm Carlsmed prices $100.5M IPO - MSN
Earnings Preview: Carlsmed to Report Financial Results Post-market on August 28 - 富途牛牛
Carlsmed appoints Jennifer Kamocsay as CLO, secretary - MSN
People moves: Michael Kaplan rejoins StandardAero as legal chief as Jenifer Kamocsay moves over to Carlsmed - | Governance Intelligence
Carlsmed names Jennifer Kamocsay as CLO and secretary - Medical Buyer
Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary - Orthopedics This Week
Carlsmed appoints Jenifer Kamocsay as chief legal officer By Investing.com - Investing.com Nigeria
Carlsmed appoints Jenifer Kamocsay as chief legal officer - Investing.com India
Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary - GlobeNewswire Inc.
Carlsmed, Inc. Selected for Inclusion in Russell 2000 Index - 富途牛牛
Carlsmed joins Russell 2000 Index following Q3 IPO - MSN
Carlsmed announces inclusion in Russell 2000 Index - TipRanks
Carlsmed, Inc. Selected for Inclusion in Russell 2000® Index - MarketScreener
AI-Powered Spine Surgery Innovator Carlsmed Joins $9T Russell 2000 Index Following Successful IPO - Stock Titan
Carlsmed, Inc.(NasdaqGS: CARL) added to Russell 3000E Growth Benchmark - MarketScreener
AI medtech firm Carlsmed to sell 6.7M shares in IPO - MSN
Goldman Sachs highlights two high-potential stocks: AI marketing platform Braze (BRZE.US) and medical technology company Carlsmed (CARL.US), assigning them a 'Buy' rating. - 富途牛牛
Carlsmed initiated with Buy at Truist on business potential - MSN
Carlsmed Q2 2025 revenue up 99% to USD 12.1M - Medical Buyer
Carlsmed stock rating reiterated at Buy by Goldman Sachs on growth outlook - Investing.com Australia
Carlsmed, Inc.: Strong Financial Performance and Growth Potential Justify Buy Rating - TipRanks
Carlsmed, Inc.: Strong Performance and Promising Growth Prospects with Upcoming Product Launch - TipRanks
Carlsmed Reports Strong Growth in Q2 2025 Earnings - TipRanks
Carlsmed 2025 Q2 Earnings Strong Revenue Growth Despite Widening Net Loss - AInvest
Carlsmed: A High-Growth AI-Driven MedTech Play in Spine Surgery - AInvest
UPDATECarlsmed® Reports Second Quarter 2025 Financial Results - The Manila Times
Earnings call transcript: Carlsmed’s Q2 2025 revenue surges, stock rises - Investing.com
Carlsmed Q2 Loss Narrows, Revenue Rises - MarketScreener
Carlsmed reports second quarter 2025 financial results - MarketScreener
Carlsmed® Q2 2025 Financial Performance: Assessing Long-Term Growth Potential in the AI-Driven Spine Surgery Revolution - AInvest
CARLSMED, INC. SEC 10-Q Report - TradingView
Carlsmed® Reports Second Quarter 2025 Financial Results - The Manila Times
Carlsmed, Inc.'s Q2 2025 Performance and Strategic Momentum: A Disruptive Force in AI-Driven Spine Surgery - AInvest
99% Growth: AI Spine Surgery Pioneer Carlsmed Hits $12.1M Revenue, Expands into Cervical Procedures - Stock Titan
Finanzdaten der Carlsmed Inc-Aktie (CARL)
Es liegen keine Finanzdaten für Carlsmed Inc (CARL) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.60%
8.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):